Article
Multidisciplinary Sciences
Guohe Song, Yang Shi, Lu Meng, Jiaqiang Ma, Siyuan Huang, Juan Zhang, Yingcheng Wu, Jiaxin Li, Youpei Lin, Shuaixi Yang, Dongning Rao, Yifei Cheng, Jian Lin, Shuyi Ji, Yuming Liu, Shan Jiang, Xiaoliang Wang, Shu Zhang, Aiwu Ke, Xiaoying Wang, Ya Cao, Yuan Ji, Jian Zhou, Jia Fan, Xiaoming Zhang, Ruibin Xi, Qiang Gao
Summary: This study characterizes the molecular classification and tumor microenvironment of intrahepatic cholangiocarcinoma (iCCA) using single cell RNA-sequencing. The authors identify S100P and SPP1 as markers for patient classification and demonstrate that different subtypes of iCCA have distinct immune cell infiltration and survival rates.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan, Yong Zeng
Summary: This study identified the role of circNFIB in intrahepatic cholangiocarcinoma (ICC) by regulating the MEK1/ERK signaling pathway to inhibit tumor growth and metastasis, suggesting its potential as a therapeutic target for ICC treatment.
Article
Gastroenterology & Hepatology
Chubin Luo, Haoyang Xin, Zhengjun Zhou, Zhiqiang Hu, Rongqi Sun, Na Yao, Qiman Sun, Uyunbilig Borjigin, Xia Wu, Jia Fan, Xiaowu Huang, Shaolai Zhou, Jian Zhou
Summary: Macrophages in ICC tumor tissues upregulate PD-L1 expression, suppressing T-cell immunity and correlating with poor survival rates. Exosomal miR-183-5p from ICC cells inhibits PTEN expression in macrophages, leading to elevated AKT phosphorylation and PD-L1 expression, contributing to ICC progression. Plasma exosomal miR-183-5p levels are associated with poor prognosis in ICC patients.
Article
Oncology
Chongqing Gao, Jing Li, Fuling Zeng, Lijuan Wang, Kaiyun Chen, Dong Chen, Jian Hong, Chen Qu
Summary: MCM6, a novel diagnostic biomarker, is upregulated in intrahepatic cholangiocarcinoma (ICC) and associated with poor prognosis. It promotes ICC progression by activating the E2F1-mediated epithelial-mesenchymal transition (EMT) and enhances the proliferation and migration of ICC cells.
Article
Plant Sciences
Li Li, Chuting Wang, Zhenpeng Qiu, Dongjie Deng, Xin Chen, Qi Wang, Yan Meng, Baohui Zhang, Guohua Zheng, Junjie Hu
Summary: This study revealed that triptolide suppresses the growth of ICC by inhibiting glycolysis via the AKT/mTOR pathway, offering a potential therapeutic target for ICC treatment.
Article
Oncology
Zheng Gao, Jia-Feng Chen, Xiao-Gang Li, Ying-Hong Shi, Zheng Tang, Wei-Ren Liu, Xin Zhang, Ao Huang, Xuan-Ming Luo, Qiang Gao, Guo-Ming Shi, Ai-Wu Ke, Jian Zhou, Jia Fan, Xiu-Tao Fu, Zhen-Bin Ding
Summary: The study shows that ERK signaling inhibition contributes to the reduction of PD-L1 expression through the autophagy pathway in intrahepatic cholangiocarcinoma (iCCA). ERK-targeted therapy may serve as a potentially novel treatment strategy for human KRAS-mutated iCCA.
CANCER CELL INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Kluempen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater
Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Sudha Kodali, Akshay Shetty, Soumya Shekhar, David W. Victor, Rafik M. Ghobrial
Summary: Cholangiocarcinoma, a tumor arising from differentiation of cholangiocytes, can develop anywhere in the biliary tree. Early diagnosis allows for surgical resection, while late-stage intrahepatic cholangiocarcinoma cases may require chemotherapy, locoregional therapies, and radiation as treatment options.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Yuki Bekki, Dagny Von Ahrens, Hideo Takahashi, Myron Schwartz, Ganesh Gunasekaran
Summary: Understanding the risk factors, patterns, and treatment options for intrahepatic cholangiocarcinoma recurrence is crucial for tailoring postoperative surveillance and selecting treatment strategies. Re-resection may be considered for selected patients at experienced centers, potentially leading to long-term survival. ICC remains a challenging disease, but advances in understanding its genomic landscape are paving the way for personalized treatment options.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Xiaolong Miao, Chen Liu, Yuancong Jiang, Yao Wang, Deqiang Kong, Zelai Wu, Xinyi Wang, Rui Tian, Xing Yu, Xuhang Zhu, Weihua Gong
Summary: ICC is a fatal malignancy with limited therapeutic options. The PI3K/mTOR pathway plays a significant role in ICC, with BEZ235 showing antitumor activity by blocking this pathway. However, BEZ235's effectiveness in inhibiting ICC progression in vivo is limited. Combination therapy with PI3K/mTOR inhibitors and BET inhibition shows promise in treating ICC by inducing M1 polarization and suppressing M2 polarization in macrophages.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Fanghua Chen, Ling Aye, Lei Yu, Longzi Liu, Yuming Liu, Youpei Lin, Dongmei Gao, Qiang Gao, Shu Zhang
Summary: Protein tyrosine phosphatases (PTPs) have been found to play a critical role in malignant transformation and metastasis. In this study, the expression and clinical significance of Slingshot homolog 1 (SSH1), a member of PTPs, were assessed in intrahepatic cholangiocarcinoma (iCCA) patients. The results revealed that elevated SSH1 expression was associated with worse overall survival and promoted iCCA progression through the p38 MAPK-CXCL8 axis.
Article
Cell Biology
Alin Garcia-Miranda, Karen Aylin Solano-Alcala, Jose Benito Montes-Alvarado, Arely Rosas-Cruz, Julio Reyes-Leyva, Napoleon Navarro-Tito, Paola Maycotte, Eduardo Castaneda-Saucedo
Summary: Autophagy is an intracellular recycling process that can be induced by leptin, a pro-tumorigenic protein, in cancer cell lines. Inhibition of autophagy reduces leptin-induced cell proliferation, migration, and ERK activation. This suggests a potential use for autophagy inhibition in breast cancer associated with obesity.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Mackenzie Owen, Mina S. Makary, Eliza W. Beal
Summary: This review examines locoregional therapy approaches for intrahepatic cholangiocarcinoma and summarizes the current literature. Locoregional therapies include thermal ablation, transarterial chemoembolization, transarterial radioembolization, external beam radiotherapy, stereotactic body radiotherapy, hepatic arterial infusion of chemotherapy, irreversible electroporation, and brachytherapy. These therapies are effective in prolonging overall survival and further research is needed to determine their comparative efficacy and optimal treatment strategies.
Review
Oncology
Amram Kupietzky, Arie Ariche
Summary: This paper reviews the surgical management of intrahepatic cholangiocarcinoma (ICC), highlighting surgical resection as the only curative treatment for ICC.
Article
Oncology
Xitao Zhang, Tianlai Liu, Jinlin Huang, Jianping He
Summary: This study revealed that PICALM promotes CRC progression through the ERK/MAPK signaling pathway, highlighting its potential as a therapeutic target in clinical applications.
CANCER CELL INTERNATIONAL
(2022)